Ohio voters reject measure that capped prices for drugs bought by the state; Senate Republicans consider keeping medical expense deduction in their tax bill; and the flu vaccine's effectiveness can be undermined by the process by which it is grown.
On election day 2017, Ohio voters rejected a measure that would curb prices of drugs bought by the state. AP reported that the measure would have ensured the state did not pay more than the Department of Veterans Affairs (VA) for prescription drugs. The VA often has deeply discounted drugs because it can negotiate prices. The pharmaceutical industry fought against the measure and put $70 million into ads attacking it.
The House tax reform bill excluded a popular medical expense deduction that Senate Republicans are considering having in their version of the tax bill. The deduction allows people to offset high healthcare costs by deducting large medical expenses in their individual income taxes, explained The Wall Street Journal. Senators Lisa Murkowski, R-Alaska, and Bill Cassidy, R-Louisiana, both noted the importance of this deduction for Americans. The Senate can only lose 2 Republican votes if it hopes to pass a bill.
This year may be one of those years when the flu vaccine offers less protection, and the process of creating vaccines may be the reason why. STAT provided an outline of how most flu vaccines are made: grown in eggs. While the process is inexpensive, it can cause issues that undermine the effectiveness of the vaccine. The vaccines are grown in hens’ eggs and mutate in order to grow, and a new study showed that last year’s disappointing vaccine was the result of a mutation that developed during the growth process in the egg.
Health Equity and Access Weekly Roundup: December 9, 2023
December 9th 2023The Center on Health Equity and Access provides information on the latest news, research discoveries, and initiatives dedicated to addressing healthcare disparities and improving overall access to high-quality care.
Read More
New TROPiCS-02 Data Back Sacituzumab Govitecan for Older Patients With Breast Cancer
December 9th 2023This phase 3 study investigated sacituzumab govitecan, a Trop-2–directed antibody-drug conjugate, vs treatment of physician’s choice in pretreated patients who have endocrine-resistant hormone receptor–positive/HER2-negative breast cancer, the most common form of breast cancer.
Read More
California Aims for Equity by Redefining Cancer Care
December 8th 2023Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.
Read More